Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter favorable biodistribution profile in non-human primates using a clinically validated editing strategy
You might also be interested in reading Bitcoin pulls away from software stocks as Iran war, AI reshape market dynamic.